ArticleJournal of translational medicine2026
FAP-targeted ROS-responsive nanoparticles delivering siBTF3 modulate the TME to enhance immunotherapy in colorectal cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tumor immunosuppressive microenvironment is a key factor limiting the efficacy of immunotherapy in colorectal cancer (CRC). This study aims to develop a novel nanodelivery system that reverses the immunosuppressive function of tumor-associated fibroblasts (CAFs) by specifically silencing basic transcription factor 3 (BTF3), thereby enhancing the antitumor immune response.
methodsCore-shell nanoparticles (NP@siBTF3) modified with fibroblast activation protein (FAP)-targeting and ROS-responsive properties were constructed for delivering BTF3 siRNA specifically into FAP-overexpressing human colorectal CAFs. The physicochemical properties of the nanoparticles were characterized using transmission electron microscopy and dynamic light scattering. Targeting efficiency was evaluated via confocal microscopy and in vivo imaging. The gene silencing efficacy, immune microenvironment remodeling effects, and antitumor activity were systematically assessed through qPCR, Western Blot, ELISA, flow cytometry, and tumor-bearing mouse models.
resultsNP@siBTF3 exhibits uniform particle size distribution, excellent serum stability, ROS-responsive release properties, and FAP-mediated targeting capability toward CAFs. In vitro experiments demonstrate its efficient silencing of BTF3 in CAFs, significantly downregulating TGF-β1 and IL-6 secretion alongside reduced expression of CAF activation markers α‑SMA and FAP. In the MC38 CRC mouse model, NP@siBTF3 treatment was associated with modulation of the tumor immune microenvironment, including increased CD8
conclusionThis study developed an intelligent nanodelivery system that may modulate the tumor-suppressive immune microenvironment by targeting and silencing BTF3 in CAFs. It suggests potential additive benefit with immune checkpoint blockade therapy, offering preliminary evidence for a potential strategy to enhance immunotherapy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.